Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18248342 | 0.92 | RIPK1 (0.88) | RIPK1 | |
| SCHEMBL28194240 | 0.92 | RIPK1 (0.81) | RIPK1 | |
| SCHEMBL18248239 | 0.90 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL18255204 | 0.90 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL18248349 | 0.90 | RIPK1 (0.98) | RIPK1 | |
| SCHEMBL18248297 | 0.90 | RIPK1 (0.93) | RIPK1 | |
| SCHEMBL20138358 | 0.89 | RIPK1 (0.89) | RIPK1 | |
| SCHEMBL18248396 | 0.89 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL18248247 | 0.89 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL22779613 | 0.87 | RIPK1 (1.00) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109882-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2024-04-04 | — | — | US | disclosed |
| US-11897876-B2 | Isoxazolidines as RIPK1 inhibitors and use thereof | GENZYME CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023083847-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-05-19 | — | — | WO | disclosed |
| CN-107624111-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-01-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20240109882-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-11897876-B2 | Isoxazolidines as RIPK1 inhibitors and use thereof | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.